Hepatitis B virus (HBV) reactivation with imatinib, a tyrosine kinase inhibitor, has been reported in chronic myeloid leukemia. Nilotinib is a more potent second generation tyrosine kinase inhibitor and it inhibits the Src-family kinase LCK and hamper proliferation and function of CD8 (+) T lymphocytes. CD8 (+) T lymphocytes are the main cellular subset responsible for viral clearance in patients with HBV infection. We report a case of HBV reactivation under treatment with nilotinib. Fatal HBV reactivation is not usually related to death in chronic myeloid leukemia patients who have an expectation of longevity with well-tolerated oral drugs. Thus, screening for latent chronic HBV infections including assessment of hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc antibody) and antibody to hepatitis B surface antigen (anti-HBs), especially at countries with intermediate and high prevalence of HBsAg is warranted. Treatment with nucleoside analogs and close monitoring may be life-saving in this context.
INTRODUCTION
Over one-third of the world's population has been exposed to hepatitis B virus (HBV) and it is estimated that there are 350 million chronic carriers worldwide. 1, 2 Reactivation of HBV is best characterized as a virological event in which there is a sudden increase in viral replication. Frequently, there is a concomitant elevation in serum aminotransferase levels and bilirubin levels in severe cases. While HBV reactivation can also occur spontaneously, the most common clinical setting involves the use of chemotherapeutic or immunosuppressive drugs. 3 Such agents are now often used in hematologic, gastrointestinal, rheumatic, dermatologic and pulmonary diseases as well as in transplantation. 4 Hepatitis B virus reactivation with imatinib, a tyrosine kinase inhibitor (TKI), has been reported in chronic myeloid leukemia (CML). [5] [6] [7] [8] [9] [10] Nilotinib is a more potent second generation TKI and we report a case of HBV reactivation after switching from imatinib to nilotinib. 
CASE REPORT

DISCUSSION
Hepatitis B virus reactivation is characterized by an abrupt rise of HBV DNA in patients with previously inactive or resolved HBV infection during or closely after chemotherapy. The current generally accepted definition of HBV reactivation following chemotherapy is the development of hepatitis with a serum ALT greater than three times the upper limit of normal or an absolute increase of 100 IU/L, associated with a demonstrable HBV DNA increase by at least 10-fold of the basal pretreatment levels. 11, 12 Hepatitis B virus reactivation not only occur in
HBsAg positive patients but this may also take place in HBsAg negative patients with anti-HBc IgG positivity and/or anti-HBs IgG positivity. 13, 14 Imatinib is a TKI that blocks the ATP binding site of BCR/ABL and is currently recommended as the first line therapy for CML. Nilotinib is a second generation TKI and was designed to overcome imatinib resistance with a better efficacy. 15 Hepatotoxicity has been reported with TKIs, however liver dysfunction usually resolves with either dose reduction or discontinuation of the drug. The mechanism of TKI-induced HBV reactivation remains unclear. In vitro studies have shown that imatinib can inhibit T-cell activation 16 and proliferation. 17 Nilotinib inhibits the Src-family kinase LCK and can hamper the proliferation and function of CD8 (+) T lymphocytes. 18, 19 Hyperbilirubinemia is a well-known side-effect of nilotinib. As increment in bilirubin levels have returned to normal grades after stopping nilotinib and did not increase despite the progressive increase in AST and ALT levels; it can be suggested that the hyperbilirubinemia might be a side effect of the treatment, the elevations of AST and ALT are also may be attributed with the hepatotoxic effect of TKI's. However, the progressive elevation in AST and ALT levels despite discontinuation of the drug, resolution of clinical findings, normalization of AST and ALT levels, negativity of HBV DNA levels after tenofovir treatment and the progress of bilirubin levels within normal ranges after restart of nilotinib therapy suggest us that the reason of hyperbilirubinemia and increment at aminotransferase levels may be due to reactivation of HBV.
Although pre-emptive treatment with nucleoside/ nucleotide analogs (NAs) before immunosuppressive treatment or anticancer cytotoxic chemotherapy is recommended, 20, 21 there was no recommendation on whether 
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